High Complexity Medical Diagnostic Laboratory, 26-Year New Jersey Lab

$10.0M

Revenue

$1.0M

SDE

6.5x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a high complexity medical diagnostic laboratory in Middlesex County, New Jersey, running as a 24/7 operation with more than 500 specimen test offerings per day. The menu skews toward higher-margin advanced work: molecular diagnostics, genetic testing, and complex liquid biopsies, plus routine infectious disease, urinalysis, and companion diagnostics. The lab holds full regulatory approvals for both routine and high-complexity testing, which is the kind of licensing (CLIA high-complexity and state approvals) that takes years and capital to build and creates a real barrier to entry.

The operation is staffed by roughly 105 employees including specialized phlebotomists, lab technicians, and technologists, and runs a private fleet of vehicles with dedicated drivers to service what the listing describes as thousands of collection centers across the Tri-State area. It accepts both in-network and out-of-network insurance and positions itself as adaptable to diverse payer models, which matters enormously to how the $10M top line actually converts to cash.

The founder has owned the business for over two decades and is exiting into retirement. At a $6.5M ask on $1M of cash flow, this is a 6.5x multiple, which is full for a services-heavy lab, so the entire investment case rests on the durability and quality of that $1M and the defensibility of the payer relationships and test volume behind it.

Why we like it

Diagnostic labs sell an essential, non-discretionary service: physicians order tests regardless of the economic cycle, and a broad 500-plus test menu spread across infectious disease, molecular, genetic, and companion diagnostics diversifies revenue away from any single test category. That is the kind of demand that holds up in a downturn better than almost any consumer-facing business.
The high-complexity CLIA and state approvals are a genuine moat. Licensing for molecular, genetic, and liquid biopsy work takes years, capital, and qualified technologists to obtain, so a buyer is acquiring regulatory standing that cannot be quickly replicated by a new entrant.
Molecular diagnostics, genetic testing, and liquid biopsy are structural growth categories driven by precision medicine and aging demographics. This lab is already positioned in the highest-value, fastest-growing segments rather than commoditized routine chemistry that gets crushed on reimbursement.
The business comes turn-key with a full management team, 105 staff, specialized phlebotomists, and a dedicated collection fleet already serving thousands of referring centers. A buyer with capital and payer-contracting skill can step in without rebuilding infrastructure, which lowers execution risk on day one.

How to improve it

Audit the payer mix immediately and quantify how much revenue and cash flow comes from out-of-network billing versus in-network contracts. Out-of-network lab revenue is fragile and under constant pressure from insurers, so the first 90 days should be spent understanding collection rates, denial rates, and days sales outstanding on every payer.
Pursue additional in-network contracts to stabilize reimbursement and reduce reliance on out-of-network balances. Converting even a portion of volume to contracted rates smooths cash flow and de-risks the revenue base, even if it trims gross realized price per test.
The listing flags that advertising is underutilized and there is a physician-referral base of thousands of centers. Build a real sales function focused on adding referring physicians, urgent care groups, and specialty practices, since incremental test volume flows through largely fixed lab overhead at high margin.
Push utilization of the higher-value molecular, genetic, and liquid biopsy panels, where reimbursement per test dwarfs routine work. Marketing these specialty capabilities to oncologists and specialists can shift the revenue mix toward the most profitable and defensible categories.
Rationalize the fleet and courier logistics against actual specimen volume by route. A private driver fleet is capital and labor intensive, so route optimization or selective third-party courier use could cut a meaningful cost line without hurting turnaround times.
Scrutinize a cash flow margin of only 10 percent on $10M of revenue. Labs with strong payer mix and utilization typically run richer, so a buyer should build a line-item plan to lift margins through denial management, staffing productivity, and reagent purchasing before assuming the 6.5x holds.

Diligence notes

Verify the CLIA certificate of compliance for high-complexity testing, all state licenses, and any accreditations (CAP, COLA), plus their transferability on a change of ownership. Confirm there are no open deficiencies, sanctions, or corrective action plans, because a lapse here can shut down revenue overnight.
Demand a full payer-level revenue and AR breakdown showing in-network versus out-of-network mix, realized collection rate per payer, denial and takeback history, and any pending audits or recoupment demands. Out-of-network lab billing carries elevated regulatory and audit risk, so this is the single most important item to confirm the quality of the $1M cash flow.
Confirm the referral concentration behind the thousands of centers claim. Understand what share of volume comes from the top referring physicians or groups, whether any referral relationships involve financial arrangements that raise anti-kickback or Stark concerns, and how sticky those relationships are post-sale.
Reconcile the reported $1M cash flow to tax returns and bank statements, and identify how much depends on the retiring founder's relationships and oversight. Given the full 6.5x multiple, scrutinize add-backs, the age and condition of the lab equipment and vehicles included, and any deferred capital expenditure on analyzers.
Investigate the reason 10 percent margins are so thin for a specialty lab and whether reimbursement rate cuts, aging equipment, or high denial rates are the cause. Also confirm employee retention risk across the 105 staff, especially licensed technologists whose departure could impair the ability to run high-complexity assays.

Source

Originally listed on BizBuySell. View original listing →